MediPharm Labs Corp.
LABS.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.12% | 5.60% | 14.88% | 14.31% | 12.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.12% | 5.60% | 14.88% | 14.31% | 12.56% |
| Cost of Revenue | 5.62% | 2.85% | 29.18% | 32.80% | 14.79% |
| Gross Profit | -7.97% | 12.06% | -9.74% | -12.28% | 8.31% |
| SG&A Expenses | -2.47% | -6.24% | -2.05% | -1.54% | -15.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 75.10% | 30.76% | -9.98% | 204.89% | 764.86% |
| Total Operating Expenses | 2.33% | -1.06% | 14.33% | 16.45% | 0.25% |
| Operating Income | -9.45% | 28.52% | -11.32% | -28.92% | 39.13% |
| Income Before Tax | -16.43% | 23.89% | 34.65% | 37.66% | 47.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.43% | 23.89% | 33.14% | 36.37% | 46.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.43% | 23.89% | 33.14% | 36.37% | 46.28% |
| EBIT | -9.45% | 28.52% | -11.32% | -28.92% | 39.13% |
| EBITDA | -25.07% | 25.71% | -39.11% | -75.50% | 44.34% |
| EPS Basic | -14.39% | 26.04% | 35.65% | 39.11% | 48.44% |
| Normalized Basic EPS | -5.06% | 30.97% | -11.69% | -27.40% | 41.91% |
| EPS Diluted | -14.39% | 26.04% | 35.65% | 39.11% | 48.44% |
| Normalized Diluted EPS | -5.06% | 30.97% | -11.69% | -27.40% | 41.91% |
| Average Basic Shares Outstanding | 2.43% | 2.55% | 4.12% | 4.33% | 4.76% |
| Average Diluted Shares Outstanding | 2.43% | 2.55% | 4.12% | 4.33% | 4.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |